The multicenter Empagliflozin, Cardiovascular Outcomes, and Mortality in T2D trial (EMPA-REG OUTCOME) has demonstrated positive effects of SGLT-2 inhibitors on CV outcomes [92]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.